CN105849101B - 新的咪唑烷-2,4-二酮衍生物 - Google Patents

新的咪唑烷-2,4-二酮衍生物 Download PDF

Info

Publication number
CN105849101B
CN105849101B CN201380081816.5A CN201380081816A CN105849101B CN 105849101 B CN105849101 B CN 105849101B CN 201380081816 A CN201380081816 A CN 201380081816A CN 105849101 B CN105849101 B CN 105849101B
Authority
CN
China
Prior art keywords
trifluoromethyl
phenyl
dimethyl
methylsulfonyl
benzonitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380081816.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN105849101A (zh
Inventor
S·欧文
C·朗科
O·杜特鲁尔
Q·晁
K·谷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Ipsen Pharma SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma SAS filed Critical Ipsen Pharma SAS
Publication of CN105849101A publication Critical patent/CN105849101A/zh
Application granted granted Critical
Publication of CN105849101B publication Critical patent/CN105849101B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201380081816.5A 2013-12-31 2013-12-31 新的咪唑烷-2,4-二酮衍生物 Expired - Fee Related CN105849101B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2013/091118 WO2015100617A1 (en) 2013-12-31 2013-12-31 Novel imidazolidine-2,4-dione derivatives

Publications (2)

Publication Number Publication Date
CN105849101A CN105849101A (zh) 2016-08-10
CN105849101B true CN105849101B (zh) 2019-02-19

Family

ID=53492968

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380081816.5A Expired - Fee Related CN105849101B (zh) 2013-12-31 2013-12-31 新的咪唑烷-2,4-二酮衍生物

Country Status (7)

Country Link
US (1) US9975880B2 (https=)
EP (1) EP3089974B1 (https=)
JP (1) JP6258508B2 (https=)
CN (1) CN105849101B (https=)
ES (1) ES2725881T3 (https=)
RU (1) RU2650678C2 (https=)
WO (1) WO2015100617A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997000071A1 (en) * 1995-06-16 1997-01-03 Biophysica Foundation Androgenic directed compositions
US20050159468A1 (en) * 2003-05-09 2005-07-21 Arwed Cleve Anti-androgenic pyrrolidines with tumor-inhibiting action
CN102428079A (zh) * 2009-04-17 2012-04-25 益普生制药股份有限公司 咪唑烷-2,4-二酮衍生物及其作为药物的用途
CN102428073A (zh) * 2009-04-17 2012-04-25 益普生制药股份有限公司 咪唑烷-2,4-二酮衍生物及其作为癌症药物的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472415B1 (en) * 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
LT2656842T (lt) * 2006-03-27 2016-09-26 The Regents Of The University Of California Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997000071A1 (en) * 1995-06-16 1997-01-03 Biophysica Foundation Androgenic directed compositions
US20050159468A1 (en) * 2003-05-09 2005-07-21 Arwed Cleve Anti-androgenic pyrrolidines with tumor-inhibiting action
CN102428079A (zh) * 2009-04-17 2012-04-25 益普生制药股份有限公司 咪唑烷-2,4-二酮衍生物及其作为药物的用途
CN102428073A (zh) * 2009-04-17 2012-04-25 益普生制药股份有限公司 咪唑烷-2,4-二酮衍生物及其作为癌症药物的用途

Also Published As

Publication number Publication date
EP3089974A4 (en) 2017-06-21
RU2650678C2 (ru) 2018-04-17
JP6258508B2 (ja) 2018-01-10
EP3089974B1 (en) 2019-02-20
RU2016131297A (ru) 2018-02-06
US20160318908A1 (en) 2016-11-03
ES2725881T3 (es) 2019-09-30
US9975880B2 (en) 2018-05-22
JP2017501193A (ja) 2017-01-12
WO2015100617A1 (en) 2015-07-09
CN105849101A (zh) 2016-08-10
EP3089974A1 (en) 2016-11-09

Similar Documents

Publication Publication Date Title
JP6967112B2 (ja) 新規なフェロポーチン阻害剤
DK2152692T3 (en) EXTERNAL anti-cancer activity
CN108774214B (zh) 作为激酶抑制剂的杂环酰胺
AU2011287574B2 (en) N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides as inhibitors of plasma kallikrein
CN107427699B (zh) 用于治疗疾病的kdm1a抑制剂
US20080139558A1 (en) Quinolones useful as inducible nitric oxide synthase inhibitors
CN105431430B (zh) Bace1抑制剂
WO2019010295A1 (en) SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF EGFR TYROSINE KINASE
JP2019519484A (ja) 芳香族スルホンアミド誘導体
CN114430743A (zh) 甲状腺激素受体β激动剂化合物
WO2020142228A1 (en) Androgen receptor protein degraders
CN115605463A (zh) 用于治疗疾病的受体相互作用蛋白激酶i的抑制剂
JP2023529867A (ja) 線維芽細胞増殖因子受容体キナーゼの阻害剤
TW201315727A (zh) 尿嘧啶衍生物及其醫藥用途
JP2018502841A (ja) Ｈｄａｃ１／２阻害剤としてのピペリジン誘導体
CA2539297C (en) Substituted triazole derivatives as oxytocin antagonists
AU2012204650A1 (en) Novel indole or indazole derivative or salt thereof
EP3490984A1 (en) 2-pyrrolidine phenylhydrazides antibacterial agents
CN112920167A (zh) 靶向fgfr和hdac的双靶点抑制剂及其制备方法和应用、药物组合物及药剂
CN105849101B (zh) 新的咪唑烷-2,4-二酮衍生物
CN113754635A (zh) 稠环类化合物及其制备方法和用途
CN101460223A (zh) 用作诱导型一氧化氮合成酶抑制剂的喹诺酮类
CN115894376B (zh) 一种芳香族酰胺类化合物、药物组合物及其用途
HK40083024A (en) Quinoline compounds with anti-cancer activity
KR20250038764A (ko) Tead 억제제 및 사용 방법

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20190219

Termination date: 20211231